ZHONGHUA YANGSHENG BAOJIAN ›› 2023, Vol. 41 ›› Issue (4): 58-62.

Previous Articles     Next Articles

Research Progress of Icariin in the Treatment of Osteoporosis

ZHU Yuan-chao1, QIN Hao-tian2, LIU Su2, CHEN Yi-xiao1, ZHANG Geng1, LIAO Shuai2, WENG Jian2, YU Fei2, ZENG Hui1,*   

  1. 1. Graduate school, Zunyi Medical University, Zunyi Guizhou, 563000, China;
    2. Department of Bone and Joint, Peking University Shenzhen Hospital, Shenzhen Guangdong, 518036, China
  • Online:2023-02-16 Published:2023-02-16

Abstract: Osteoporosis is a chronic disease characterized by bone loss and structural damage of bone tissue. It has a high incidence rate in middle-aged and elderly people, especially in postmenopausal women. The disease seriously threatens the physical and mental health of patients and brings heavy burden to their families. Because of its side effects and high price, the use of drugs for the treatment of osteoporosis has been affected. Epimedium, a traditional Chinese medicine, is safe to use and easy to obtain. It is widely used in the treatment of orthopedic diseases. Previous studies have confirmed that icariin, the main component of epimedium, has a good application prospect in the treatment of osteoporosis. It can promote the proliferation and differentiation of osteoblasts and BMSCs by up regulating the expression of osteogenic markers ALP, RUNX2, BMP-2, etc., and achieve bone regeneration and bone formation. In this process, Wnt/ β- Catenin, OPG/RANK/RANKL and other signaling pathways play an important role. Based on this, this article reviews the effect and possible mechanism of icariin on osteoporosis.

Key words: icariin, osteoporosis, osteogenic markers, Wnt/β-catenin signaling pathway, OPG/RANK/RANKL signaling pathway

CLC Number: